Objective: Current Society for Vascular Surgery guidelines, based on randomized controlled trials published more than a decade ago, recommend a minimum threshold diameter of 5.5 cm for infrarenal abdominal aortic aneurysm (iAAA) repair. It is unknown whether practice patterns with respect to size of repair have changed since the publication of these guidelines. We aimed to evaluate the real-world practice of vascular surgeons in our region with respect to iAAA size at the time of repair, whether this has changed during the past 12 years, and if any changes were associated with the repair type, open vs endovascular.
Methods: The Vascular Study Group of New England (VSGNE) database was used to identify all patients receiving iAAA repair between 2003 and 2015. Primary end point was to quantify the annual percentage of iAAAs repaired in different size categories (>5.5 cm; <5.5 cm but >5.0 cm; <5.0 cm) during the study period and by type of repair. Secondary end points were morbidity and mortality in these groups. We excluded nonelective cases (ruptured or symptomatic), patients with coexisting iliac artery aneurysms, and those missing critical data.
Results: During the study period, 5314 patients with iAAA repairs (1538 open; 3776 endovascular) were identified in the VSGNE database. In 40% (2110/5314) of patients, repair was performed for aneurysms <5.5 cm, with endovascular aneurysm repair (EVAR) in 75% (1581/2110) and open repair in 25% (529/2110). More EVARs were performed for aneurysms <5.5 cm in 2015 (46%) compared with 2003 (33%; P < .05, n À 1 c 2 ), with an average increase of 1.1%/y. There was also a nonstatistically significant increase in open repair of small aneurysms (0.7%/y; P ¼ .759). Overall 30-day mortality was 1.11% in the EVAR group (0.54% in <5.0 cm, 0.91% in >5.0 cm but <5.5 cm, and 1.55% in >5.5 cm) compared with 3% in the open group (2.88%, 1.79%, and 3.77%, respectively), with no significant change in mortality in either group over time.
Conclusions: Despite Society for Vascular Surgery guidelines suggesting surveillance rather than repair of iAAA <5.5 cm, an increasing proportion of repairs in the VSGNE database were performed below that threshold. The reasons for this are likely multifactorial and might include a lesser complexity and lower operative mortality for smaller aneurysms and markedly improved third-and fourth-generation stent graft technology with possibly better long-term survival. As such, it may be time to reexamine current guidelines for iAAA repair. Objective: The 2013 American College of Cardiology/American Heart Association Updated Practice Guidelines recommend the use of highdose statins in all patients <75 years with chronic limb-threatening ischemia (CLTI) and moderate-dose statins in CLTI patients >75 years without contraindications or on hemodialysis, but these recommendations are based primarily on stroke and coronary data. We aimed to validate these guidelines in patients with CLTI and to assess current adherence to these recommendations.
Methods:
We identified all patients with CLTI who underwent first-time revascularization (endovascular or open) at a single institution from 2005 to 2014. Patients were classified as high-dose, moderate, low, or no statin postoperatively on the basis of the American College of Cardiology/ American Heart Association guidelines. Major adverse limb event (MALE)-free survival (death, amputation, or major reintervention), overall survival, and amputations were recorded. Cox regression was used to account for differences in baseline characteristics.
Results: After excluding patients on hemodialysis, we identified 1033 limbs from 945 patients with a median follow-up of 380 days. Patients receiving recommended doses had higher rates of preoperative statin use, coronary artery disease, chronic kidney disease, stroke, atrial fibrillation, congestive heart failure, and coronary artery bypass grafting and lower smoking rates, and they were less likely to be ambulatory preoperatively (all P < .05). Overall, only 35% were taking the recommended statin dose; 55% of those older than 75 years were taking a moderate dose, and 20% of those younger than 75 years were taking a high dose. In univariate analysis, patients receiving the recommended doses had lower rates of survival (P ¼ .01) but no difference in rates of amputation, MALE-free survival, or reintervention and amputation (all P > .05). After adjustment for confounders, Cox regression demonstrated a 23% increase in the rate of MALE-free survival for patients taking recommended doses (hazard ratio, 0.77 [95% confidence interval, 0.61-0.97]; P ¼ .03; Fig) . Both subgroups of patients (>75 years on moderate dose and <75 years on high dose) accrued similar benefit from compliance with guidelines.
Conclusions: Compliance with recent guidelines is associated with significantly decreased limb events or death in patients undergoing revascularization for CLTI. Although adherence is increasing, two-thirds of eligible patients are not taking recommended doses, a potential target for improvement. Abstracts
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